Abstract ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug resistance of some cancer cells. Despite significant research in ABC transporters in the context of many diseases, little is known about their expression and clinical value in glioblastoma (GBM). We analyzed expression of 49 ABC transporters in both commercial and patient-derived GBM cell lines as well as from 51 human GBM tumor biopsies. Using The Cancer Genome Atlas (TCGA) cohort as a training dataset and our cohort as a validation dataset, we also investigated the prognostic value of these ABC transporters in newly diagnosed GBM patients, treated with the standard of care. In contrast to commercial GBM cell lines, GBM-patient derived cell lines (PDCL), grown as neurospheres in a serum-free medium, express ABC transporters similarly to parental tumors. Serum appeared to slightly increase resistance to temozolomide correlating with a tendency for an increased expression of ABCB1. Some differences were observed mainly due to expression of ABC transporters by microenvironmental cells. Together, our data suggest that the efficacy of chemotherapeutic agents may be misestimated in vitro if they are the targets of efflux pumps whose expression can be modulated by serum. Interestingly, several ABC transporters have prognostic value in the TCGA dataset. In our cohort of 51 GBM patients treated with radiation therapy with concurrent and adjuvant temozolomide, ABCA13 overexpression is associated with a decreased progression free survival in univariate (p < 0.01) and multivariate analyses including MGMT promoter methylation (p = 0.05) suggesting reduced sensitivity to temozolomide in ABCA13 overexpressing GBM. Expression of ABC transporters is: (i) detected in GBM and microenvironmental cells and (ii) better reproduced in GBM-PDCL. ABCA13 expression is an independent prognostic factor in newly diagnosed GBM patients. Further prospective studies are warranted to investigate whether ABCA13 expression can be used to further personalize treatments for GBM.
Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults, with a median overall survival below 20 months after the initial diagnosis [1] . Virtually, all GBM patients experience tumor relapse after first-line standard of care. The blood-brain barrier (BBB), a biophysical barrier limiting penetration of chemotherapeutic agents within the brain and the brain tumor, is one of the actors involved in intrinsic resistance of drugs in GBM patients [2] .
ATP binding cassette (ABC) transporters are a family of 49 proteins that actively transport many substrates. This family contains the main efflux pumps that expel drugs out of cells, therefore impacting chemosensitivity [3] . Efflux pumps are expressed by many cells in the body. In the brain, they are expressed by microglial cells, astrocytes, neurons, pericytes and, endothelial cells [4] . Endothelial cells, which are involved in the normal functioning of the BBB, mainly express ABCB1 (P-gp) and ABCG2 (BCRP) to efflux xenobiotics from the brain parenchyma to the bloodstream [2] . In addition, many ABC transporters are involved in cell metabolism and/or transport of biologic molecules [3] .
ABC transporters have a large spectrum of substrates, including many chemotherapeutic agents [5] . The efflux of these therapeutic agents from the brain to the blood by the BBB hampers their access to tumor cells and their efficacy. Efflux pumps, from the ABC transporter family, can also be expressed by tumor cells themselves, leading to the development of intrinsic chemoresistance [6] .
Here the expression of all ABC transporters in GBM cells and their microenvironment was assessed and their potential prognostic impact in a homogeneous population of GBM patients was further investigated.
Materials and methods

Public dataset
Levels of mRNA expression of the 49 ABC transporters were downloaded from The Cancer Genome Atlas (TCGA) GBM dataset [7] . The threshold of z-scores (RNA Seq V2 RSEM) was set at ± 2 of distinguishing over-and underexpressing samples. Overall survival (OS; from diagnosis to death) and progression-free survival (PFS; from diagnosis to first tumor progression) were compared using log-rank test. P values below 0.05 were considered significant. RNAseq data for the U251 cell line were obtained from Lundberg et al. [8] . Expression levels of ABCB1, ABCG1 and ABCG2 by normal CNS cells were obtained from http://web.stanf ord.edu/group /barre s_lab/brain _rnase q.html [9] .
OncoNeuroTek tissue and data as validation cohort
For the validation, patients and tumors from the OncoNeuroTek tissue bank were selected according to the following inclusion criteria : (i) newly diagnosed and histologically proven GBM, (ii) age below 70 years, (iii) Karnofsky performance status above 70%, (iv) treated with radiation therapy with concurrent and adjuvant temozolomide [10] , (v) available MGMT promoter methylation status, (vi) available clinical data, (vii) available tumor tissue for additional molecular analysis and, (viii) signed informed consent form for molecular analysis.
GBM cell lines
Nine GBM-patient derived cell lines (PDCL) named 4339, 4371, 5706, 6190, 6240, 7015, 7060, 7142 and N13-1520 were established in our laboratory. Tissue from the paired human tumor samples was available for further molecular analysis. These samples and associated clinico-molecular annotations were previously reported [11] .
Cell culture
Cell cultures were performed as previously described [11] . GBM-PDCL were established (passage > 5) and cultured in DMEM-F12 (Life Technologies, 31331028) supplemented with 1% penicillin/streptomycin, B27 supplement 50X (Life Technologies, 17504-044), 20 ng/mL human bFGF (Peprotech, 100-18B) and 20 ng/mL human EGF (Peprotech, 100-15). Cells were cultured as gliomaspheres. Dissociation was performed with Accutase StemPro (Life Technologies, A11105-11) after washing with HBSS (Life Technologies, 1150029). For culture in serum, PDCL were cultured in DMEM (Life Technologies, 31885049) supplemented with 10% FBS (Thermo Fisher Life) and 1% penicillin/ streptomycin.
Viability test
For drug sensitivity assays, 96-well plates were used. For viability assay on PDCL, wells were coated with 10 µg/mL laminin (cat no. L2020, Sigma-Aldrich) at 37 °C for 1 h for PDCL. Six thousand cells were plated per well. Temozolomide (Sigma-Aldrich, T2577) was resuspended in DMSO as a 20 mg/mL stock solution and was added 24 h after plating. 150 h after drug addition, WST-1 reagent (Roche) was added according to the manufacturer's instructions. WST-1 salt is cleaved to a soluble formazan dye by a NAD(P)H-dependent reaction in viable cells. Plates were incubated for 3 h and read by spectrophotometry at 450 and 620 nm wavelength.
RNA extraction
RNA samples from the 9 GBM tumors and their nine paired GBM-PDCL were provided by OncoNeuroTek tissue bank. RNA extraction for tumor samples was performed as previously described using the RNeasy Lipid Tissue Mini Kit (Qiagen) [12] .
For GBM-PDCL, 1 × 10 4 dissociated cells were cultured in a 75 cm 2 flask for 4 days, with culture medium changed at day 3, and cells were harvested the next day as a dry pellet and stored at − 80 °C as described previously [11] . RNA extraction was performed using the kit NucleoSpin® RNA (Macherey-Nagel, 740955) according the manufacturer's guidelines.
Reverse transcription and real-time quantitative PCR (RT-qPCR)
Reverse transcription was performed using the kit Maxima First Strand cDNA Synthesis Kit for RT-qPCR (ThermoScientific, K1442) according to the manufacturer's guidelines starting with 750 ng of RNA. cDNAs were stored at − 20 °C.
qPCR was used to examine expression levels of ABCA13, ABCB1, ABCG1, and ABCG2 in the GBM-PDCL cells. Paired tumor samples were analyzed using the LightCycler Probe Master mix 2× (Roche, 04887301001) and the UPL detection system (Roche, 04483433001; primers are listed in Supplementary Table 1) in a Light Cycler 96 (Roche). For each qPCR, we made a duplicate measure in each experiment and we ran three distinct experiments at three different passages. PPIA expression was used for normalization. qPCR was used to investigate expression levels of ABCA1, ABCA4, ABCA13, ABCC1, ABBCC12, ABCC13, and ABCG1 in the validation cohort of GBM patients were performed in a 1534 wells plate using a Sybr green detection system in a Light Cycler 1534 (Roche). PPIA and PPIB expression were used for normalization.
Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue sections were deparaffinized, rehydrated, and incubated in citrate buffer at pH 4.0 for epitope retrieval in a microwave at 400 W for 15 min. Blockade solution was made using PBS 0.1M supplemented with 0.4% triton, 3% BSA and 10% donkey serum. Anti-human ABCG2 antibody (BXP-21; Euromedex) and anti-human CD31 antibody (SP38; Thermo Fischer Scientific) were diluted at 1:100 in the blockade solution and incubated on the tissue slices overnight at 4 °C. Secondary antibodies conjugated with Alexa 488 and 447 were incubated on the slices for 2 h at room temperature. The slices were then mounted using fluoromount, supplemented with DAPI (0100-20; Clinisciences) and visualized using a microscope (Apotome Axio M2, Zeiss).
Statistical analysis
Comparison between ABC transporter expression in GBM-PDCL and tumors was performed by a paired t-test with a Bonferroni correction using R.
RT-qPCR data bar charts were plotted with GraphPad PRISM 4, and analyzed by a two-way ANOVA test.
For analysis of OS and PFS, patients were divided in two groups from each side of the median. Kaplan-Meier survival curves were made on GraphPad PRISM 4. Survivals of groups with "low" versus "high" expression were compared using Log-rank (Mantel-Cox) test. Additional Cox test for survival in a multivariate modality was performed with R to assess the impact of MGMT promoter methylation status after a log2 transformation of ABCA13 expression.
Results
Expression of ABC transporters in the commercial U251 GBM cell line, in GBM-PDCL and paired-GBM tumors
Out of the 49 ABC transporters, 19 are measurably expressed in U251 GBM cell lines versus 42/49 in the GBM-PDCL line [8] . This highlights that GBM cell lines may lose ABC transporter expression over time in adherent culture conditions including bovine fetal serum (Fig. 1, Panel A) . When cultured in a differentiating medium containing fetal calf serum, the N13-1520 PDCL shows a slight non-significant trend for increased expression of ABCB1 in RT-qPCR (Fig. 1c) associated with higher resistance to temozolomide in an in vitro viability assay (p < 0.0001) (Fig. 1d) . These results suggest that the expression loss of most of the ABC transporters may be due to the high passages after cell line establishment rather than exposure to fetal calf serum. It also highlights the importance of using a non-differentiating serum-free medium.
We already showed that, overall, GBM-PDCL are molecularly very close to their parental human tumors in a multi-omics analysis when cultured in a non-differentiating serum-free medium [11] . We analyzed the same data set (i.e. 9 GBM-PDCL and their tumor of origin) with a specific focus on expression levels of the 49 ABC transporters acquired using Affymetrix® expression profiling microarray and RNA Seq platforms. Three ABC transporters were differentially expressed between the GBM-PDCL and their parental tumor in both transcriptomes (i.e. Affymetrix and RNA Seq): ABCB1, ABCG1 and ABCG2 (Figs. 1b, 2a, b ; Table 1 ).
RT-qPCR validated the difference of expression for the three transporters ( Fig. 2c-e; Supplementary Fig. 1 ).
ABC transporters differentially expressed in GBM-PDCL compared to their parental tumors are expressed in the microenvironnement
We hypothesized that ABC transporters are differentially expressed between GBM-PDCL and their parental tumors (i.e. underexpression in GBM-PDCL versus paired human tumors) due to the expression by microenvironmental cells present in bulk tumor. We questioned http://web.stanf ord. edu/group /barre s_lab/brain _rnase q.html for expression of ABCB1, ABCG1 and ABCG2 in normal murine cells [13] . ABCB1, ABCG1 and ABCG2 are expressed by endothelial cells supporting our hypothesis. ABCG1 and ABCG2 are also expressed in additional cell types (i.e. astrocytes, neurons, oligodendrocytes) (Fig. 2e-g ). Indeed, ABCG2 and CD31 expression are colocalized using immunohistochemistry in a human GBM (Fig. 2h) .
Clinical value of ABC transporter expression in GBM patients
We then investigated the prognostic value of the 49 ABC transporters in the 2013 TCGA GBM cohort. An overview of the expression of these transporters is presented in Supplementary Fig. 2 . Kaplan-Meier analysis highlighted an unfavorable prognostic impact of: (i) over-expression of ABCA1, ABCA4, ABCC12 and ABCG1 on OS and (ii) over-expression of ABCA13, ABCC1 and ABCC13 on PFS (Table 2) .
To validate this finding, expression of ABCA1, ABCA4, ABCA13, ABCC1, ABCC12, ABCC13 and ABCG1 was assessed in a homogeneously treated cohort of 51 newly diagnosed GBM patients (Fig. 3a) . Only overexpression of ABCA13 was validated as negative prognostic factor in terms of PFS (p = 0.004, Fig. 3b ) and OS in univariate analysis (p = 0.047, Fig. 3c ). In multivariate analysis, ABCA13 overexpression was found to be an independent poor prognostic factor of PFS (p = 0.05 for ABCA13, HR = 1.12) when MGMT promoter methylation status (p = 0.002 for MGMT, HR = 3.13) is included in the statistical model, but not for OS.
Discussion
Glioblastoma is a challenging cancer to treat. Indeed, GBM cells are highly resistant to treatments. The blood-brain and blood-tumor barriers limit the efficacy of drug treatments in GBM patients and are a major factor in primary resistance of GBM cells to chemotherapy.
The blood-brain and blood-tumor barriers are physical and biological barriers. ABC transporters play a pivotal role in the biology of both barriers. Indeed, they can expel chemotherapeutic agents from the brain tissue to the bloodstream [2] . Expression of ABC transporters by the tumor cells themselves can also be responsible for tumor resistance to chemotherapies. Therefore, in the current work we have investigated their expression in GBM cell lines used for preclinical investigations of new therapeutic compounds and in human tumors.
Commercial GBM cell lines lack expression of most ABC transporters. Additional in vitro models that better recapitulate ABC transporter expression patterns of human tumors must be also used before moving drugs to in vivo investigations. GBM-PDCL is an important tool expressing a larger number of ABC transporters expressed in human GBM. However, addition of serum in the culture medium appeared to change expression patterns of ABC transporters. A trend to the increased expression of ABCB1 and an increased resistance to temozolomide in a serumcomplemented medium is consistent with the fact that Bar charts in panels F, G and H represent the expression of ABCB1, ABCG1 and ABCG2 respectively by the different cell types in the brain extracted from a database [9] . E endothelial cells, M Microglia, MO myelinating oligodendrocytes, NFO newly formed oligodendrocytes, OPC oligodendrocyte progenitor cells, N neurons, A astrocytes. Panel I shows colocalization of ABCG2 and CD31 in immunofluorescence in a human GBM temozolomide is a substrate of ABCB1 [14] . Together, our data suggest that the efficacy of chemotherapeutic agents might be changed in vitro, if they are substrates of efflux pumps not expressed in the cell line used and whose expression can be modulated by fetal calf serum. Using GBM-PDCL closer to human GBM may reduce this overestimation and may be more relevant. To identify ABC transporters impacting response to the standard of care of newly diagnosed GBM patients, we have correlated prognosis of GBM patients to ABC transporter expression in a training dataset (i.e. TCGA) and a validation dataset (i.e. personal cohort). ABCA13 expression was found to be a prognostic factor for PFS and OS in univariate analyses. Interestingly, based on multivariate analysis, ABCA13 expression provides additional prognostic information, in terms of PFS, to MGMT promoter methylation in young patients (< 70 years), in good clinical condition (KPS > 70%) suffering from newly diagnosed GBM and treated with the standard of care. This supports for the first time ABCA13 expression as an independent prognostic biomarker in newly diagnosed GBM patients. Additional prospective and functional studies are warranted to investigate our findings further.
Little is known about ABCA13. ABCA13 is a large protein of 5058 amino acids encoded by ABCA13 located on chromosome region 7p12.3 that is often polysomic in GBM.
ABCA13 is highly expressed in the bone marrow, but not in normal brain [9] . Therefore, in GBM, ABCA13 is likely to be primarily expressed by tumor cells rather than microenvironmental cells. The molecular function of ABCA13 remains largely unknown [15] . However, ABCA13 has been linked to multiple human diseases, including cancer. ABCA13 genetic polymorphisms have been associated with psychiatric disorders [16] [17] [18] [19] [20] [21] and success of coronary artery bypass surgery [22] . ABCA13 expression has also been linked to outcome in various cancers. In line with our study, ABCA13 overexpression is associated with poor prognosis in renal cell carcinoma [23] , in gastric adenocarcinoma [24] , and in ovarian serous carcinoma [25] . In contrast, ABCA13 overexpression is associated with improved outcomes in breast cancer [26] and in colorectal cancer [27] . Yun et al. reported an association of ABCA13 and stem-like phenotype in the "side population" of metastatic renal cell carcinoma. Overexpression of ABCA13 was also correlated with drug resistance, suggesting a potential role in drug efflux [23] .
Overall our study suggests that ABC binding cassette transporters, particularly ABCA13, are important in both preclinical and clinical research in GBM. We have found that ABCA13 is a potential prognostic factor in GBM patients and a putative actor of therapy resistance.Further studies are warranted to support our findings and to better understand the role of ABCA13. ABCA13 overexpression is significantly associated with shorter OS. Panel C: ABCA13 overexpression is significantly associated with shorter PFS
